Arbutus Biopharma Corp
ABUS evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $1.03B
- Lead Asset:
- AB-101 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ABUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABUS
Arbutus Biopharma Corp (ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, primarily developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, while actively enforcing its intellectual property rights related to lipid nanoparticle technology.
Key risk: Low cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 1 catalyst for Arbutus Biopharma Corp.
Arbutus Biopharma Corp (ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, primarily developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, while actively enforcing its intellectual property rights related to lipid nanoparticle technology.
- Cash & equivalents of $19.2M as of 2026-06-30 [sec].
- Total revenue of $1.0M and net loss of -$5.1M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of $258.7M as of 2026-06-30 [sec].
- Imdusiran (AB-729) is a Phase 2 RNAi therapeutic for chronic hepatitis B, with FDA Fast Track designation [pipeline][news].
- AB-101 is a Phase 1 oral PD-L1 inhibitor for chronic hepatitis B [pipeline].
What works
- Imdusiran (AB-729) has shown durable viral control: 94% of long-term follow-up patients remain off all treatment for up to 2+ years [news].
- FDA granted Fast Track designation to imdusiran, which may facilitate development and accelerate FDA review [news].
- The company has reduced net cash burn: $14.1M used in operating activities for H1 2026 vs $29.1M for H1 2025, a decrease of $15.0M [sec_mda].
- Arbutus has a strong intellectual property portfolio, with ongoing patent enforcement actions against Pfizer/BioNTech and Moderna [sec_mda].
What to weigh
- Cash & equivalents are relatively low at $19.2M as of 2026-06-30, and the company expects to require substantial additional funds to continue pipeline development [sec][sec_mda].
- Net loss of -$5.1M for H1 2026 indicates ongoing operating losses [sec].
- The company faces significant litigation costs related to patent claims against Pfizer/BioNTech, Moderna, and the United States [sec_mda].
- Imdusiran faces competition from at least two other Phase 2 candidates for chronic hepatitis B [pipeline].
From the filings
Quoted directly from source documents.
Imdusiran Phase 2 data on durable viral control
“94% of long-term follow-up patients remain off all treatment for up to 2+ years”
News · November 13, 2025
Reduced cash burn in H1 2026 vs H1 2025
“For the six months ended June 30, 2026, $14.1 million of cash was used in operating activities compared to $29.1 million used in operating activities for the six months ended June 30, 2025”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2032-08-15 · Patent_Expiry · TENOFOVIR ALAFENAMIDE FUMARATE — Patent_Expiry: NDA208464 — Expiration of a patent related to tenofovir alafenamide fumarate; may affect competitive landscape for hepatitis B treatments.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of $19.2M as of 2026-06-30 may not sustain operations without additional funding [sec].
- Ongoing net losses — Net loss of -$5.1M for H1 2026 indicates continued operating losses [sec].
- Litigation costs — Costs from patent lawsuits against Pfizer/BioNTech, Moderna, and the US could strain finances [sec_mda].
- Competition in hepatitis B — Imdusiran faces at least two Phase 2 competitors for chronic hepatitis B [pipeline].
What to watch
- Imdusiran (AB-729) Phase 2 clinical data updates and potential regulatory milestones [pipeline][news].
- Outcome of patent litigation against Pfizer/BioNTech and Moderna, which could provide significant financial upside [sec_mda].
- Cash burn rate and any new financing or partnership deals to extend runway [sec_mda].
- AB-101 Phase 1 clinical progress as an oral PD-L1 inhibitor for chronic hepatitis B [pipeline].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Arbutus Biopharma Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arbutus Biopharma Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~2132d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
168
Total value held
$625.1M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 25,891,480 | $116.5M |
| two seas capital lp | 18,557,543 | $83.5M |
| whitefort capital management, lp | 14,930,885 | $67.2M |
| blackrock, inc. | 12,966,946 | $58.4M |
| vanguard capital management llc | 6,688,911 | $30.1M |
| rubric capital management lp | 6,626,389 | $29.8M |
| state street corp | 6,342,510 | $28.5M |
| barclays plc | 4,316,095 | $19.4M |
| geode capital management, llc | 3,771,806 | $17.0M |
| adar1 capital management, llc | 3,133,175 | $14.1M |
Showing top 10 of 168 institutional holders of Arbutus Biopharma Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.4%
- Days to cover
- 8.8
- Shares short
- 17,743,389
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABUS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arbutus Biopharma Corp?
Arbutus Biopharma Corp (ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, primarily developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, while actively enforcing its intellectual property rights related to lipid nanoparticle technology.
What is Arbutus Biopharma Corp's lead drug candidate?
Arbutus Biopharma Corp's most advanced tracked candidate is AB-101 (Phase 1) for Chronic Hepatitis b.
What is Arbutus Biopharma Corp's next catalyst?
Arbutus Biopharma Corp's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208464" — expected August 15, 2032.
Who is the CEO of Arbutus Biopharma Corp?
Ms. Lindsay Androski J.D., M.B.A. is the chief executive officer of Arbutus Biopharma Corp (ABUS).
Where is Arbutus Biopharma Corp headquartered?
Arbutus Biopharma Corp (ABUS) is headquartered in Warminster, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.